Complement activation in the Parkinson's disease substantia nigra: An immunocytochemical study

Journal of Neuroinflammation

Volumn 3, Issue , 2006, Pages

  Loeffler, David A ^a   Camp, Dianne M ^a   Conant, Stephanie B ^a,b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C9; DOPAMINE; NEUROMELANIN;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CELL COUNT; CELL LOSS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DISEASE DURATION; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LEWY BODY; MAJOR CLINICAL STUDY; NERVE CELL; NEUROPROTECTION; NONPARAMETRIC TEST; PARKINSON DISEASE; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA;

EID: 33750802218     PISSN: 17422094     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-3-29     Document Type: Article

References (46)

1. Beal MF: Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann NY Acad Sci 2003, 991:120-31.
2. McGeer PL, Itagaki S, Boyes BE, McGeer EG: Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-91.
3. Teismann P, Schulz JB: Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 2004, 318:149-61.
4. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y: Distribution of major histocompatibility class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol (Berl) 2003, 106:518-26.
5. McGeer PL, Itagaki S, Akiyama H, McGeer EG: Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988, 24:574-6.
6. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T: Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994, 180:147-50.
7. Nagatsu T, Mogi M, Ichinose H, Togari A: Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 2000, 60:277-90.
8. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A: The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156:50-61.
9. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH: Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003, 18:2731-42.
10. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A: Non-steroidal anti-inflammatory drugs and the risk of Parkinson's disease. Arch Neurol 2003, 60:1059-64.
11. Chen H, Jacobs E, Schwarzschild MA, McGullough ML, Calle EE, Thun MJ, Ascherio A: Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 2005, 58:963-7.
12. Ton TG, Heckbert SR, Longstreth WT Jr, Rossing MA, Kukull WA, Franklin GM, Swanson PD, Smith-Weller T, Checkoway H: Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov Disord 2006, 21:964-9.
13. Yao J, Harvath L, Gilbert DL, Colton CA: Chemotaxis by a CNS macrophage, the microglia. J Neurosci Res 1990, 27:36-42.
14. Nolte C, Moller T, Walter T, Kettenmann H: Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton. Neuroscience 1996, 73:1091-107.
15. Grondahl G, Hohannisson A, Jensen-Waern M, Nilsson Ekdahl K: Opsonization of yeast cells with equine iC3b, C3b, and IgG. Vet Immunol Immunopathol 2001, 80:209-23.
16. Cunnion KM, Zhang HM, Frank MM: Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect Immun 2003, 71:656-62.
17. Erdei A, Andrasfalvy M, Peterfy H, Toth G, Pecht I: Regulation of mast cell activation by complement-derived peptides. Immunol Lett 2004, 92:39-42.
18. Shen Y, Halperin JA, Lee CM: Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res 1995, 671:282-292.
19. McGeer PL, McGeer EG: The possible role of complement activation in Alzheimer disease. Trends Mol Med 2002, 9:519-23.
20. Shen Y, Meri S: Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol 2003, 70:463-72.
21. Yamada T, McGeer PL, McGeer EG: Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol (Berl) 1992, 84:100-4.
22. Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K: Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry. Neurosci Lett 2000, 286:69-73.
23. Rozemuller AJ, Eikelenboom P, Theeuwes JW, Jansen Steur EN, de Vos RA: Activated microglial cells and complement factors are unrelated to cortical Lewy bodies. Acta Neuropathol (Berl) 2000, 100:701-8.
24. Fasano M, Bergamasco B, Lopiano L: Modifications of the iron-neuromelanin system in Parkinson's disease. J Neurochem 2006, 96:909-16.
25. Kingsbury AE, Marsden CD, Foster OJ: The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: an in situ hybridization study. Mov Disord 1999, 14:206-18.
26. Wright SP: Adjusted P-values for simultaneous inference. Biometrics 1992, 48:1005-1013.
27. Humbles AA, Lu B, Nilsson CA, Lilly C, Israel E, Fujiwara Y, Gerard NP, Gerard C: A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000, 406:998-1001.
28. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, Szebeni J, Alving CR, Carroll MC, Berkower I, Stojilkovic SS, Metcalfe DD: F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003, 9:431-8.
29. Soto E, Romero R, Richani K, Espinoza J, Nien JK, Chaiworapongsa T, Santolava-Forgas J, Edwin SS, Mazor M: Anaphylatoxins in preterm and term labor. J Perinat Med 2005, 33:306-13.
30. Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP: Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 2000, 49:171-86.
31. van Beek J, Nicole O, Ali C, Ischenko A, MacKenzie ET, Buisson A, Fontaine M: Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport 2001, 12:289-93.
32. Heese K, Hock C, Otten U: Inflammatory signals induce neurotrophin expression in human microglial cells. J Neurochem 1998, 70:699-707.
33. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J: Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 1997, 18:415-21.
34. Robert-Offerman SR, Leers MP, van Suylen RJ, Nap M, Daemen MJ, Theunissen PH: Evaluation of the membrane attack complex of complement for the detection of a recent myocardial infarction in man. J Pathol 2000, 191:48-53.
35. Xi G, Hua Y, Keep RF, Younger JG, Hoff JT: Brain edema after intracerebral hemorrhage: the effects of systemic complement depletion. Acta Neurochir Suppl 2002, 81:253-6.
36. Schultz SJ, Aly H, Hasanen BM, Khashaba MT, Lear SC, Bendon RW, Gordon LE, Feldhoff PW, Lassiter HA: Complement component 9 activation, consumption, and neuronal deposition in the post-hypoxic-ischemic central nervous system of human newborn infants. Neurosci Lett 2005, 378:1-6.
37. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM: A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005, 128:2665-74.
38. Collard CD, Montalto MC, Reenstra WR, Buras JA, Shahl GL: Endothelial oxidative stress activates the lectin complement pathway: role of cytokeratin 1. Am J Pathol 2001, 159:1045-54.
39. Floor E, Wetzel MG: Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 1998, 70:268-75.
40. Cohen G: Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 1984, 5:77-82.
41. Hila S, Soane L, Koski CL: Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD. Glia 2001, 36:58-67.
42. Badea TD, Park JH, Soane L, Niculescu T, Nuculescu F, Rus H, Shin ML: Sublytic terminal complement attack induces c-fos transcriptional activation in myotubes. J Neuroimmunol 2003, 142:58-66.
43. Rus H, Cudrici C, Niculescu F: C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection. Ann Med 2005, 37:97-104.
44. Cudrici C, Niculescu F, Jensen T, Zafranskaia E, Fosbrink M, Rus V, Shin ML, Rus H: C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J Immunol 2006, 176:3173-80.
45. van Beek J, van Meurs M, 't Hart BA, Brok HP, Neal JW, Chatagner A, Harris CL, Omidvar N, Morgan BP, Laman JD, Gasque P: Decay-accelerating factor (CD55) is expressed by neurons in response to chronic but not acute autoimmune central nervous system inflammation associated with complement activation. J Immunol 2005, 174:2353-65.
46. Boos L, Campbell IL, Ames R, Wetsel RA, Barnum SR: Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J Immunol 2004, 173:4708-14.